NCT05107492View on ClinicalTrials.gov

Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

April 9, 2022

Study Completion Date

April 9, 2022

Conditions
Inflammatory Bowel Disease
Interventions
DRUG

450mg

following a single subcutaneous dose of PF-06480605 450 mg

DRUG

150mg

following a single subcutaneous dose of PF-06480605 150 mg

DRUG

Placebo

following a single subcutaneous dose of placebo

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05107492 - Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants | Biotech Hunter | Biotech Hunter